Use access key #2 to skip to page content.
$2.32 -0.01 (-0.43%)
12/3/2008 3:59 PM

Trimeris, Inc. (TRMS)

CAPS Rating:
****

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors.

View All Commentary (TRMS)

Recs

0

Avatar zzlangerhans (99.39) Submitted: 7/16/08 2:05 PM : Underperform Start Price: $5.70 TRMS Score: 29.57

Recent developments seem to indicate that Trimeris is planning to close up shop as Fuzeon sales diminish. They've terminated all R&D activity and are distributing out their cash to shareholders as dividends. Who would buy the company, and for what reason? Fuzeon has nowhere to go but down. The pick is a little complicated because I'm not sure how CAPS accounts for dividends, but I'm fairly sure the share price is eventually headed for the sub 1's. The only question is why it isn't there already.

Report this Post Replies: 1 | Reply | Permalink

Avatar zzlangerhans (99.39) Submitted: 11/14/08 2:28 PM

Recs: 0 | Rec This

Trimeris is going to 0 but my points will likely max out around 50 and it could take 2 years. Basically I made my point and I'm tired of looking at the pick.

Report this Post Reply

Featured Broker Partners

Sponsored Links